Rheumatology (Oxford)

• 

  Publication Venue For

  • Treatment failure in inflammatory arthritis: time to think about syndemics?.  58:1526-1533. 2019
  • The SLE-key test serological signature: new insights into the course of lupus..  57:1632-1640. 2018
  • Power in numbers..  57:v40-v47. 2018
  • The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy..  57:v2-v8. 2018
  • Challenges and controversies of complex interventions in osteoarthritis management: recognizing inappropriate and discordant care..  57:iv88-iv98. 2018
  • The impact of menopause on functional status in women with rheumatoid arthritis..  57:798-802. 2018
  • 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects..  56:1884-1893. 2017
  • Biosimilars in rheumatology: understanding the rigor of their development..  56:187-197. 2017
  • Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab..  56:247-254. 2017
  • Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing..  56:156-164. 2017
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab..  55:1710. 2016
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab..  55:991-999. 2016
  • Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2..  55:1145-1147. 2016
  • Suppression of inflammatory disease activity in rheumatoid arthritis is associated with improvements in retinal microvascular health..  55:246-251. 2016
  • Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study..  53:1613-1617. 2014
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study..  51:2204-2214. 2012
  • Microparticles as mediators and biomarkers of rheumatic disease..  51:1737-1746. 2012
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial..  51:1628-1638. 2012
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX..  51:1226-1234. 2012
  • Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis..  50:1732-1736. 2011
  • Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker of disease activity and cardiovascular risk?.  50:939-943. 2011
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis..  48:1114-1121. 2009
  • Health-related quality of life in children and adolescents with juvenile localized scleroderma..  48:670-672. 2009
  • Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis..  48:513-519. 2009
  • A large kindred of early-onset osteoarthritis of the knee and hip: excluding the link to COL2A1 gene..  48:371-374. 2009
  • Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel..  47:194-199. 2008
  • The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. 2018